
InflaRx N.V. – NASDAQ:IFRX
InflaRx N.V. stock price today
InflaRx N.V. stock price monthly change
InflaRx N.V. stock price quarterly change
InflaRx N.V. stock price yearly change
InflaRx N.V. key metrics
Market Cap | 141.91M |
Enterprise value | 203.61M |
P/E | -7.55 |
EV/Sales | N/A |
EV/EBITDA | -6.08 |
Price/Sales | N/A |
Price/Book | 1.88 |
PEG ratio | -0.59 |
EPS | -0.69 |
Revenue | N/A |
EBITDA | -43.51M |
Income | -40.88M |
Revenue Q/Q | N/A |
Revenue Y/Y | N/A |
Profit margin | 0% |
Oper. margin | 0% |
Gross margin | 0% |
EBIT margin | 0% |
EBITDA margin | N/A |
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeInflaRx N.V. stock price history
InflaRx N.V. stock forecast
InflaRx N.V. financial statements
Jun 2023 | 0 | -8.20M | |
---|---|---|---|
Sep 2023 | 60.80K | -7.45M | -12255% |
Dec 2023 | 2.22K | -15.52M | -696965.02% |
Mar 2024 | 36.24K | -9.71M | -26798.21% |
Dec 2023 | 2.22K | -15.52M | -696965.02% |
---|---|---|---|
Mar 2024 | 36.24K | -9.71M | -26798.21% |
Sep 2025 | 324.71K | -14.39M | -4433.97% |
Dec 2025 | 689.52K | -14.97M | -2171.57% |
Analysts Price target
Financials & Ratios estimates
Jun 2023 | 132964505 | 8.31M | 6.26% |
---|---|---|---|
Sep 2023 | 129485304 | 11.49M | 8.88% |
Dec 2023 | 120307660 | 17.64M | 14.66% |
Mar 2024 | 107194489 | 12.34M | 11.52% |
Jun 2023 | -11.16M | -24.30M | 53.14M |
---|---|---|---|
Sep 2023 | -5.25M | 7.37M | -94.28K |
Dec 2023 | -10.29M | 2.98M | -94.90K |
Mar 2024 | -14.95M | 27.10M | -86.21K |
InflaRx N.V. alternative data
Aug 2023 | 44 |
---|---|
Sep 2023 | 44 |
Oct 2023 | 44 |
Nov 2023 | 44 |
Dec 2023 | 44 |
Jan 2024 | 44 |
Feb 2024 | 44 |
Mar 2024 | 62 |
Apr 2024 | 62 |
May 2024 | 62 |
Jun 2024 | 62 |
Jul 2024 | 62 |
InflaRx N.V. other data
InflaRx: Small German Company Targeting A Rare Indication
Organigram And Rounding Out My Tax Loss Selling Basket
Week In Review: Kelun-Biotech In $9.5 Billion ADC Deal With Merck
Achilles Therapeutics: The First Full Position In My Tax Loss Selling Basket
InflaRx:Â On Watch For A Buy During Tax Loss Selling Season
InflaRx And Vilobelimab In AAV: Avoiding Clinical Hard Knocks
-
What's the price of InflaRx N.V. stock today?
One share of InflaRx N.V. stock can currently be purchased for approximately $0.86.
-
When is InflaRx N.V.'s next earnings date?
Unfortunately, InflaRx N.V.'s (IFRX) next earnings date is currently unknown.
-
Does InflaRx N.V. pay dividends?
No, InflaRx N.V. does not pay dividends.
-
How much money does InflaRx N.V. make?
InflaRx N.V. has a market capitalization of 141.91M.
-
What is InflaRx N.V.'s stock symbol?
InflaRx N.V. is traded on the NASDAQ under the ticker symbol "IFRX".
-
What is InflaRx N.V.'s primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of InflaRx N.V.?
Shares of InflaRx N.V. can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
How many employees does InflaRx N.V. have?
As Jul 2024, InflaRx N.V. employs 62 workers.
-
When InflaRx N.V. went public?
InflaRx N.V. is publicly traded company for more then 7 years since IPO on 7 Nov 2017.
-
What is InflaRx N.V.'s official website?
The official website for InflaRx N.V. is inflarx.de.
-
How can i contact InflaRx N.V.?
InflaRx N.V. can be reached via phone at +49 3641 508180.
InflaRx N.V. company profile:

InflaRx N.V.
inflarx.deNASDAQ
62
Biotechnology
Healthcare
InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology primarily in Germany and the United States. The company's C5a is an inflammatory mediator that is involved in the progression of a variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody, which completed the Phase III clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; for the treatment of anti-neutrophil cytoplasm antibody associated vasculitis, a rare and life-threatening autoimmune disease that is in Phase II trial; to treat pyoderma gangraenosum, a chronic inflammatory skin disorder that is in Phase IIa exploratory study; and for the treatment of PD-1/PD-L1 inhibitor resistant/refractory locally advanced or metastatic cutaneous squamous cell carcinoma that is in Phase II clinical development stage. The company also develops INF904, an oral, small molecule drug candidate for the undisclosed chronic inflammatory and autoimmune diseases; and IFX002 that is in pre-clinical development stage for the treatment of chronic inflammation and autoimmune diseases. It has co-development agreement with Beijing Defengrei Biotechnology Co. Ltd.; and clinical trial collaboration and supply agreement with Merck & Co. Inc. The company was formerly known as Fireman B.V. and changed its name to InflaRx N.V. in 2017. InflaRx N.V. was founded in 2007 and is headquartered in Jena, Germany.
Jena, 07745
CIK: 0001708688
ISIN: NL0012661870
CUSIP: N44821101